Lycia Therapeutics Inc.

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the closing of its upsized initial public offering of 20,286,000 shares of its common stock, which includes the exercise in …

As investors wait for the Claude developer to file its official IPO paperwork, several biotechs are going public and doing just fine.

One biotech IPO debuted this week, while four IPOs submitted initial filings, including two sizable biotech filings. One IPO is currently scheduled for the week ahead as investors continue to hold their breath for the year's last potential mega IPO. Street research is expected for two companies in the week ahead, and six lock-up periods will be expiring.

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the pricing of its upsized initial public offering of 17,640,000 shares of its common stock at an initial public offering pr…

Drug developer Lycia Therapeutics targets $938 million valuation in US IPO